This is the official Google+ page for Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies.
Teva's net revenues in 2014 amounted to $20.3 billion. For more information, visit www.tevapharm.com.
Note to Users: This page is intended to provide news and updates about our company, and Teva reserves the right to delete any comments that it considers to be inappropriate, abusive or spam.
Adverse events for any of our products should be reported to: Safety.AE@teva.co.il
Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details may be found here: http://tevapharm.com/contact_us/
新年好 / 新年好
“In 2014 we solidified the foundation. 2015 was transformative with a series of strategically compelling Business Development transactions, and in 2016 we are moving ahead with integrations and more selective business partnerships. In 2017, we'll shift gears and move to the next phase in the grand story of Teva.”